Optimi Health (TSE:OPTI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Optimi Health Corp. and Psyence Biomedical Ltd. have announced their intention to partner, with Optimi set to become the exclusive supplier of GMP nature-derived psilocybin extract for Psyence’s FDA-approved palliative care therapies. The collaboration aims to support Psyence’s clinical trials and regulatory submissions in advancing psilocybin-based mental health treatments. While the letter of intent is non-binding, the successful execution of a binding agreement could lead to transformative treatments within the palliative care sector.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.